$AMSC
AMERICAN SUPERCONDUCTOR CORP /DE/ Stock $amsc

$amsc Overview Financials Valuation SEC Filings Company Website

2013 Q2 Form 10-Q Financial Statement

#000119312513324142 Filed on August 07, 2013

Income Statement

Concept	2013 Q2	2013 Q1	2012 Q2
Revenue	$23.09M	$20.42M	$28.72M
YoY Change	-19.61%	-28.68%	216.95%
Cost Of Revenue	$17.99M	$18.09M	$16.93M
YoY Change	6.27%	-27.84%	-0.2%
Gross Profit	$5.099M	$2.330M	$11.79M
YoY Change	-56.75%	-34.55%	-249.24%
Gross Profit Margin	22.09%	11.41%	41.06%
Selling, General & Admin	$10.83M	$13.35M	$13.80M
YoY Change	-21.54%	-22.25%	-37.25%
% of Gross Profit	212.34%	572.96%	117.04%
Research & Development	$3.027M	$3.850M	$3.910M
YoY Change	-22.58%	-35.08%	-51.97%
% of Gross Profit	59.36%	165.24%	33.16%
Depreciation & Amortization	$2.655M	$2.910M	$3.344M
YoY Change	-20.6%	-36.46%	3.21%
% of Gross Profit	52.07%	124.89%	28.36%
Operating Expenses	$31.94M	$17.28M	$34.84M
YoY Change	-8.35%	-25.45%	14.51%
Operating Profit	-$8.850M	-$14.95M	-$6.128M
YoY Change	44.42%	-23.8%	-84.01%
Interest Expense	$2.100M	-$3.320M	$2.700M
YoY Change	-22.22%	482.46%	1025.0%
% of Operating Profit
Other Income/Expense, Net	$69.00K	-$10.00K	$123.0K
YoY Change	-43.9%		-78.42%
Pretax Income	-$10.42M	-$19.35M	-$11.11M
YoY Change	-6.19%	-7.77%	-70.39%
Income Tax	$90.00K	$420.0K	-$836.0K
% Of Pretax Income
Net Earnings	-$10.51M	-$19.77M	-$10.28M
YoY Change	2.32%	-6.61%	-72.73%
Net Earnings / Revenue	-45.54%	-96.82%	-35.78%
Basic Earnings Per Share	-$1.80		-$0.20
Diluted Earnings Per Share	-$1.80	-$3.505M	-$0.20
COMMON SHARES
Basic Shares Outstanding	58.30M shares		51.19M shares
Diluted Shares Outstanding	58.30M shares		51.19M shares

Balance Sheet

Concept	2013 Q2	2013 Q1	2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$32.60M	$39.20M	$65.70M
YoY Change	-50.38%	-24.03%	-58.1%
Cash & Equivalents	$32.61M	$39.24M	$60.49M
Short-Term Investments		$0.00	$5.200M
Other Short-Term Assets	$24.70M	$28.60M	$47.20M
YoY Change	-47.67%	-18.98%	-29.24%
Inventory	$30.75M	$33.47M	$28.70M
Prepaid Expenses
Receivables	$11.09M	$18.86M	$13.60M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$99.14M	$120.2M	$155.1M
YoY Change	-36.08%	-16.31%	-41.71%
LONG-TERM ASSETS
Property, Plant & Equipment	$71.93M	$74.63M	$87.70M
YoY Change	-17.98%	-17.81%	-11.05%
Goodwill
YoY Change
Intangibles	$2.536M	$2.749M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$9.067M	$9.020M	$17.90M
YoY Change	-49.35%	-46.63%	-19.73%
Total Long-Term Assets	$95.05M	$96.57M	$109.1M
YoY Change	-12.88%	-13.39%	-14.5%
TOTAL ASSETS
Total Short-Term Assets	$99.14M	$120.2M	$155.1M
Total Long-Term Assets	$95.05M	$96.57M	$109.1M
Total Assets	$194.2M	$216.8M	$264.2M
YoY Change	-26.5%	-15.03%	-32.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.174M	$7.146M	$30.90M
YoY Change	-86.49%	-12.85%	-53.46%
Accrued Expenses	$21.10M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due	$11.70M	$8.800M	$3.600M
YoY Change	225.0%
Total Short-Term Liabilities	$67.51M	$79.76M	$84.10M
YoY Change	-19.72%	-7.58%	-35.7%
LONG-TERM LIABILITIES
Long-Term Debt	$5.800M	$9.200M	$19.90M
YoY Change	-70.85%
Other Long-Term Liabilities	$1.165M	$1.291M	$3.500M
YoY Change	-66.71%	-65.11%	34.62%
Total Long-Term Liabilities	$1.165M	$1.291M	$23.40M
YoY Change	-95.02%	-65.11%	800.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$67.51M	$79.76M	$84.10M
Total Long-Term Liabilities	$1.165M	$1.291M	$23.40M
Total Liabilities	$75.71M	$91.64M	$107.8M
YoY Change	-29.77%	1.59%	-19.49%
SHAREHOLDERS EQUITY
Retained Earnings	-$810.6M	-$800.1M
YoY Change
Common Stock	$610.0K	$603.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$370.0K	$313.0K
YoY Change
Treasury Stock Shares
Shareholders Equity	$118.5M	$125.1M	$156.4M
YoY Change
Total Liabilities & Shareholders Equity	$194.2M	$216.8M	$264.2M
YoY Change	-26.5%	-15.03%	-32.89%

Cashflow Statement

Concept	2013 Q2	2013 Q1	2012 Q2
OPERATING ACTIVITIES
Net Income	-$10.51M	-$19.77M	-$10.28M
YoY Change	2.32%	-6.61%	-72.73%
Depreciation, Depletion And Amortization	$2.655M	$2.910M	$3.344M
YoY Change	-20.6%	-36.46%	3.21%
Cash From Operating Activities	-$9.307M	-$4.580M	-$11.59M
YoY Change	-19.7%	-41.06%	-79.94%
INVESTING ACTIVITIES
Capital Expenditures	$97.00K	-$170.0K	$88.00K
YoY Change	10.23%	-91.01%	-101.86%
Acquisitions
YoY Change
Other Investing Activities	$205.0K	$2.830M	-$6.760M
YoY Change	-103.03%	-191.59%	-110.48%
Cash From Investing Activities	$3.774M	$2.660M	-$6.846M
YoY Change	-155.13%	-153.41%	-111.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net	$1.154M
YoY Change
Cash From Financing Activities	-1.211M	-1.040M	32.93M
YoY Change	-103.68%	-677.78%	651.71%
NET CHANGE
Cash From Operating Activities	-9.307M	-4.580M	-11.59M
Cash From Investing Activities	3.774M	2.660M	-6.846M
Cash From Financing Activities	-1.211M	-1.040M	32.93M
Net Change In Cash	-6.744M	-2.960M	14.49M
YoY Change	-146.55%	-76.45%	127.8%
FREE CASH FLOW
Cash From Operating Activities	-$9.307M	-$4.580M	-$11.59M
Capital Expenditures	$97.00K	-$170.0K	$88.00K
Free Cash Flow	-$9.404M	-$4.410M	-$11.68M
YoY Change	-19.48%	-25.0%	-77.98%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	63124801	shares
CY2012Q1	us-gaap	Restructuring Reserve RestructuringReserve	974000
CY2012Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	5896000
CY2012Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	46279000
CY2012Q2	us-gaap	Share Price SharePrice	3.97
CY2012Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	25000000
CY2012Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	3800000
CY2013Q1	us-gaap	Share Price SharePrice	2.67
CY2013Q1	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	1440000
CY2013Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	15380000
CY2013Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	9142000
CY2013Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	923847000
CY2013Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	7146000
CY2013Q1	us-gaap	Notes Payable Current NotesPayableCurrent	4158000
CY2013Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2442000
CY2013Q1	us-gaap	Deferred Tax Liabilities Current DeferredTaxLiabilitiesCurrent	5444000
CY2013Q1	us-gaap	Restructuring Reserve RestructuringReserve	199000
CY2013Q1	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	2709000
CY2013Q1	us-gaap	Liabilities Current LiabilitiesCurrent	79757000
CY2013Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1112000
CY2013Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	2709000
CY2013Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	4162000
CY2013Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5506000
CY2013Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1291000
CY2013Q1	us-gaap	Stockholders Equity StockholdersEquity	125118000
CY2013Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent
CY2013Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	5881000
CY2013Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	30138000
CY2013Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	529000
CY2013Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-800131000
CY2013Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	29805000
CY2013Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	4610000
CY2013Q1	us-gaap	Common Stock Value CommonStockValue	603000
CY2013Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	216754000
CY2013Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	133000
CY2013Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	3367000
CY2013Q1	us-gaap	Liabilities Liabilities	91636000
CY2013Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1340000
CY2013Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2013Q1	us-gaap	Deferred Tax Assets Gross Noncurrent DeferredTaxAssetsGrossNoncurrent	5354000
CY2013Q1	us-gaap	Assets Current AssetsCurrent	120185000
CY2013Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	4820000
CY2013Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2749000
CY2013Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	9020000
CY2013Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	6136000
CY2013Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	3427000
CY2013Q1	us-gaap	Assets Assets	216754000
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39243000
CY2013Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	5966000
CY2013Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18864000
CY2013Q1	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	1642000
CY2013Q1	us-gaap	Inventory Net InventoryNet	33473000
CY2013Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	22469000
CY2013Q1	us-gaap	Billed Contract Receivables BilledContractReceivables	17222000
CY2013Q1	us-gaap	Inventory For Long Term Contracts Or Programs InventoryForLongTermContractsOrPrograms	2425000
CY2013Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	18649000
CY2013Q1	us-gaap	Treasury Stock Value TreasuryStockValue	313000
CY2013Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	21655000
CY2013Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	74626000
CY2013Q1	amsc	Convertible Notes Payable Current Net ConvertibleNotesPayableCurrentNet	4289000
CY2013Q1	amsc	Convertible Notes Payable Noncurrent Net ConvertibleNotesPayableNoncurrentNet	600000
CY2013Q1	amsc	Warrant Liabilities WarrantLiabilities	3633000
CY2013Q1	amsc	Notes Payable Noncurrent Net NotesPayableNoncurrentNet	95000
CY2013Q1	amsc	Notes Payable Current Net NotesPayableCurrentNet	458000
CY2013Q1	amsc	Accrued Outside Services AccruedOutsideServices	2251000
CY2013Q1	amsc	Accrued Value Added Tax Current AccruedValueAddedTaxCurrent	809000
CY2012Q2	us-gaap	Share Price SharePrice	4.68
CY2012Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	25278000
CY2012Q2	us-gaap	Restructuring Reserve RestructuringReserve	578000
CY2012Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	5500000
CY2012Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	4500000
CY2012Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	35000000
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	60487000
CY2012Q3	us-gaap	Share Price SharePrice	4.15
CY2012Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	24191000
CY2012Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	2800000
CY2012Q4	us-gaap	Share Price SharePrice	2.62
CY2012Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	20944000
CY2012Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	1000000
CY2013Q2	us-gaap	Share Price SharePrice	2.64
CY2013Q2	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	1179000
CY2013Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	14389000
CY2013Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	9419000
CY2013Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	927807000
CY2013Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	4174000
CY2013Q2	us-gaap	Notes Payable Current NotesPayableCurrent	4252000
CY2013Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	512000
CY2013Q2	us-gaap	Deferred Tax Liabilities Current DeferredTaxLiabilitiesCurrent	5452000
CY2013Q2	us-gaap	Restructuring Reserve RestructuringReserve	76000
CY2013Q2	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	2787000
CY2013Q2	us-gaap	Liabilities Current LiabilitiesCurrent	67514000
CY2013Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1077000
CY2013Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	2787000
CY2013Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	3693000
CY2013Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4153000
CY2013Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1165000
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	118480000
CY2013Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent
CY2013Q2	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	3532000
CY2013Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	25481000
CY2013Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	477000
CY2013Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-810644000
CY2013Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	20031000
CY2013Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	7426000
CY2013Q2	us-gaap	Common Stock Value CommonStockValue	610000
CY2013Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	194193000
CY2013Q2	us-gaap	Line Of Credit Facility Amount Outstanding LineOfCreditFacilityAmountOutstanding	2700000
CY2013Q2	us-gaap	Line Of Credit Facility Amount Outstanding LineOfCreditFacilityAmountOutstanding	3500000
CY2013Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	175000
CY2013Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	2268000
CY2013Q2	us-gaap	Liabilities Liabilities	75713000
CY2013Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1234000
CY2013Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2013Q2	us-gaap	Deferred Tax Assets Gross Noncurrent DeferredTaxAssetsGrossNoncurrent	5421000
CY2013Q2	us-gaap	Assets Current AssetsCurrent	99140000
CY2013Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	6098000
CY2013Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2536000
CY2013Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	9067000
CY2013Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	824000
CY2013Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	3730000
CY2013Q2	us-gaap	Assets Assets	194193000
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32608000
CY2013Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	6423000
CY2013Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11088000
CY2013Q2	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	1863000
CY2013Q2	us-gaap	Inventory Net InventoryNet	30752000
CY2013Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	23868000
CY2013Q2	us-gaap	Billed Contract Receivables BilledContractReceivables	9225000
CY2013Q2	us-gaap	Inventory For Long Term Contracts Or Programs InventoryForLongTermContractsOrPrograms	2685000
CY2013Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	18658000
CY2013Q2	us-gaap	Treasury Stock Value TreasuryStockValue	370000
CY2013Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	17914000
CY2013Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	71931000
CY2013Q2	amsc	Convertible Notes Payable Current Net ConvertibleNotesPayableCurrentNet	3259000
CY2013Q2	amsc	Convertible Notes Payable Noncurrent Net ConvertibleNotesPayableNoncurrentNet	172000
CY2013Q2	amsc	Warrant Liabilities WarrantLiabilities	3216000
CY2013Q2	amsc	Notes Payable Noncurrent Net NotesPayableNoncurrentNet	39000
CY2013Q2	amsc	Notes Payable Current Net NotesPayableCurrentNet	363000
CY2013Q2	amsc	Accrued Outside Services AccruedOutsideServices	2744000
CY2013Q2	amsc	Performance Bond Value PerformanceBondValue	200000
CY2013Q2	amsc	Derivative Liability Additional Convertible Notes And Warrants DerivativeLiabilityAdditionalConvertibleNotesAndWarrants	15000000
CY2013Q2	amsc	Number Of Performance Bonds In Support Of Customer Contracts NumberOfPerformanceBondsInSupportOfCustomerContracts	1	Bonds
CY2013Q2	amsc	Accrued Value Added Tax Current AccruedValueAddedTaxCurrent	1517000
CY2013Q2	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	1800000
CY2011Q2	us-gaap	Loss Contingency New Claims Filed Number LossContingencyNewClaimsFiledNumber	4	Claim
CY2011Q2	us-gaap	Loss Contingency New Claims Filed Number LossContingencyNewClaimsFiledNumber	7	Claim
CY2011Q2	amsc	Number Of Complaint Additionally Asserted Claims Against Underwriters NumberOfComplaintAdditionallyAssertedClaimsAgainstUnderwriters	1	Claim
CY2011Q2	amsc	Number Of Officers Putative Securities Filed Against NumberOfOfficersPutativeSecuritiesFiledAgainst	2	Employees
CY2013	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.57	pure
CY2012Q2	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P2Y6M
CY2012Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-11111000
CY2012Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1168000
CY2012Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4132000
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	-10275000
CY2012Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11591000
CY2012Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	51191000	shares
CY2012Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6300000	shares
CY2012Q2	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	806000	shares
CY2012Q2	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0.160	pure
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2012Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-136000
CY2012Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1164000
CY2012Q2	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1016000
CY2012Q2	us-gaap	Payments For Restructuring PaymentsForRestructuring	524000
CY2012Q2	us-gaap	Sales Revenue Net SalesRevenueNet	28716000
CY2012Q2	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.750	pure
CY2012Q2	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0044	pure
CY2012Q2	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0.150	pure
CY2012Q2	amsc	Fair Value Assumptions Redeemable FairValueAssumptionsRedeemable	yes
CY2012Q2	amsc	Fair Value Assumptions Dilution Effect FairValueAssumptionsDilutionEffect	yes
CY2012Q2	amsc	Fair Value Assumptions Recovery Rate FairValueAssumptionsRecoveryRate	0.300	pure
CY2012Q2	amsc	Percentage Volume Condition Met PercentageVolumeConditionMet	0.859	pure
CY2012Q2	amsc	Convertible Notes Fair Value As Percentage Of Par Value ConvertibleNotesFairValueAsPercentageOfParValue	0.151	pure
CY2011Q3	amsc	Loss Contingency Number Of Claims Consolidated LossContingencyNumberOfClaimsConsolidated	3	Claim
CY2013Q1	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P1Y6M4D
CY2013Q1	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.669	pure
CY2013Q1	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0020	pure
CY2013Q1	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0.165	pure
CY2013Q1	amsc	Fair Value Assumptions Redeemable FairValueAssumptionsRedeemable	yes
CY2013Q1	amsc	Fair Value Assumptions Dilution Effect FairValueAssumptionsDilutionEffect	yes
CY2013Q1	amsc	Fair Value Assumptions Recovery Rate FairValueAssumptionsRecoveryRate	0.300	pure
CY2013Q1	amsc	Percentage Volume Condition Met PercentageVolumeConditionMet	0.805	pure
CY2013Q1	amsc	Convertible Notes Fair Value As Percentage Of Par Value ConvertibleNotesFairValueAsPercentageOfParValue	0.034	pure
CY2012Q2	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P2Y3M11D
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.009	pure
CY2012Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
CY2012Q2	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.710	pure
CY2012Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	51191000	shares
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.720	pure
CY2012Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
CY2012Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M24D
CY2012Q2	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0033	pure
CY2012Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-2718000
CY2012Q2	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-848000
CY2012Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	-812000
CY2012Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-11439000
CY2012Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	123000
CY2012Q2	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	-167000
CY2012Q2	us-gaap	Income Taxes Paid IncomeTaxesPaid	-828000
CY2012Q2	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	-229000
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6128000
CY2012Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	88000
CY2012Q2	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	6858000
CY2012Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	4000
CY2012Q2	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-6449000
CY2012Q2	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2282000
CY2012Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	32925000
CY2012Q2	us-gaap	Inventory Write Down InventoryWriteDown	250000
CY2012Q2	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-3913000
CY2012Q2	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	14208000
CY2012Q2	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1994000
CY2012Q2	us-gaap	Interest Expense InterestExpense	2700000
CY2012Q2	us-gaap	Cost Of Revenue CostOfRevenue	16926000
CY2012Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6846000
CY2012Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3910000
CY2012Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3344000
CY2012Q2	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	32961000
CY2012Q2	us-gaap	Restructuring Charges RestructuringCharges	128000
CY2012Q2	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	900000
CY2012Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1994000
CY2012Q2	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	100000
CY2012Q2	us-gaap	Restructuring Settlement And Impairment Provisions RestructuringSettlementAndImpairmentProvisions	128000
CY2012Q2	us-gaap	Restructuring Costs RestructuringCosts	-39000
CY2012Q2	us-gaap	Other Noncash Expense OtherNoncashExpense	200000
CY2012Q2	us-gaap	Deferred Policy Acquisition Cost Amortization Expense DeferredPolicyAcquisitionCostAmortizationExpense	81000
CY2012Q2	us-gaap	Operating Expenses OperatingExpenses	34844000
CY2012Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13799000
CY2012Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-836000
CY2012Q2	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-280000
CY2012Q2	amsc	Weighted Average Shares Of Common Stock Outstanding WeightedAverageSharesOfCommonStockOutstanding	51997000	shares
CY2012Q2	amsc	Fair Value Assumptions Redeemable FairValueAssumptionsRedeemable	yes
CY2012Q2	amsc	Fair Value Assumptions Dilution Effect FairValueAssumptionsDilutionEffect	yes
CY2012Q2	amsc	Fair Value Assumptions Recovery Rate FairValueAssumptionsRecoveryRate	0.300	pure
CY2012Q2	amsc	Losses On Purchase Commitments LossesOnPurchaseCommitments	-7301000
CY2012Q2	amsc	Payments In Lieu Of Issuance Of Common Stock For Payroll Taxes PaymentsInLieuOfIssuanceOfCommonStockForPayrollTaxes	-36000
CY2012Q2	amsc	Percentage Volume Condition Met PercentageVolumeConditionMet	0.752	pure
CY2012Q2	amsc	Gain Loss In Change Of Fair Value Of Derivative Instruments And Warrants GainLossInChangeOfFairValueOfDerivativeInstrumentsAndWarrants	-2388000
CY2012Q2	amsc	Non Cash Interest Expense Amortization Of Debt Discount NonCashInterestExpenseAmortizationOfDebtDiscount	2300000
CY2012Q2	amsc	Convertible Notes Fair Value As Percentage Of Par Value ConvertibleNotesFairValueAsPercentageOfParValue	0.179	pure
CY2013Q2	dei	Entity Registrant Name EntityRegistrantName	AMERICAN SUPERCONDUCTOR CORP /DE/
CY2013Q2	dei	Amendment Flag AmendmentFlag	false
CY2013Q2	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2013Q2	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2013Q2	dei	Document Type DocumentType	10-Q
CY2013Q2	dei	Document Period End Date DocumentPeriodEndDate	2013-06-30
CY2013Q2	dei	Entity Central Index Key EntityCentralIndexKey	0000880807
CY2013Q2	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2013Q2	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2013Q2	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P1Y3M4D
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.017	pure
CY2013Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
CY2013Q2	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.658	pure
CY2013Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58300000	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.746	pure
CY2013Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2013Q2	us-gaap	Nature Of Operations NatureOfOperations	<div> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>1.</b></font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Nature of the Business and Operations and Liquidity</b></font></td> </tr> </table> <!-- xbrl,body --> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Nature of the Business and Operations</i></b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">American Superconductor Corporation (“AMSC” or the “Company”) was founded on April 9, 1987. The Company is a leading provider of megawatt-scale solutions that lower the cost of wind power and enhance the performance of the power grid. In the wind power market, the Company enables manufacturers to field wind turbines through its advanced engineering, support services and power electronics products. In the power grid market, the Company enables electric utilities and renewable energy project developers to connect, transmit and distribute power through its transmission planning services and power electronics and superconductor-based products. The Company’s wind and power grid products and services provide exceptional reliability, security, efficiency and affordability to its customers.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">These unaudited condensed consolidated financial statements of the Company have been prepared on a going concern basis in accordance with United States generally accepted accounting principles (“GAAP”) and the Securities and Exchange Commission’s (“SEC”) instructions to Form 10-Q. The going concern basis of presentation assumes that the Company will continue operations and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. Certain information and footnote disclosures normally included in the financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been condensed or omitted pursuant to those instructions. The year-end condensed balance sheet data was derived from audited financial statements but does not include all disclosures required by GAAP. The unaudited condensed consolidated financial statements, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary for a fair statement of the results for the interim periods ended June 30, 2013 and 2012 and the financial position at June 30, 2013.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Liquidity</i></b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company has experienced recurring operating losses and as of June 30, 2013, the Company had an accumulated deficit of $810.6 million. In addition, the Company has experienced recurring negative operating cash flows, which has resulted in a decrease in its cash balance. These factors raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments that might result from the outcome of this uncertainty. At June 30, 2013, the Company had cash and cash equivalents of $32.6 million. Cash used in operations for the three months ended June 30, 2013 was $9.3 million. The Company obtained financing totaling approximately $35.0 million during the quarter ended June 30, 2012. No additional financing has been obtained since then.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company is currently in the process of consolidating certain business operations to reduce facility costs. The Company expects that its cost reduction efforts and anticipated revenue growth will result in a reduction of cash used for operations during the fiscal year ending March 31, 2014, compared to the prior year. In July 2013, the Company reduced its workforce by approximately 7% and expects to record a restructuring charge for severance and other costs of approximately $1.0 million in the quarter ending September 30, 2013. The Company plans to closely monitor its expenses and if required, expects to further reduce operating costs and capital spending to enhance liquidity.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">On April 4, 2012, the Company completed a private placement of $25.0 million aggregate principal amount of a 7% senior unsecured convertible note (the “Initial Note”). On June 5, 2012, the Company entered into a Loan and Security Agreement (the “Term Loan”), under which the Company borrowed $10.0 million. On December 20, 2012, the Company agreed to exchange the Initial Note for a new unsecured, senior convertible note (the “Exchanged Note”), which had the same principal amount and accrued interest as the Initial Note at the time of the exchange. See Note 10, “Debt”, for further information regarding these debt arrangements, including the covenants, restrictions and events of default under the agreements.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">On June 5, 2012, the Company entered into a Loan and Security Agreement (as modified by that certain Limited Waiver dated June 11, 2013, the “Term Loan”), under which the Company borrowed $10.0 million. The Term Loan contains certain covenants and restrictions including, among others, a requirement to maintain a minimum unrestricted cash balance in the U.S. equal to the remaining principal balance. (See Note 10, “Debt”, for further information regarding these debt arrangements, including the covenants, restrictions and events of default under the agreements.) The Company believes that it is in compliance with the covenants and restrictions included in the agreements governing these debt arrangements as of the date of this Quarterly Report on Form 10-Q.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In order for the Company to continue operations beyond the next twelve months and be able to discharge its liabilities and commitments in the normal course of business, the Company needs to significantly increase sales through executing its strategy to broaden its customer base, enter new markets, and commercialize its superconductor product line. In addition, the Company may need to further reduce operating expenses in line with business conditions in order to decrease the amount of cash used in operations and continue to work with the holder of its convertible note in order to maintain the ability to make monthly amortization payments on the convertible note in shares of common stock. In July 2013, the holder of the Exchanged Note converted $4.0 million of the Exchanged Note into shares of common stock in accordance with the accelerated payment provisions of the Exchanged Note. In addition, the Company is actively seeking to sell its minority investments in Tres Amigas and Blade Dynamics and has recently engaged a financial advisor to assist with that effort. (See Note 13, “Equity Investments”, for further information about such investments.) There can be no assurance that we will be able to sell one or both of these investments on commercially reasonable terms or at all.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">If the Company successfully executes on its plans discussed above, then the Company believes that its available cash, together with additional reductions in operating costs and capital expenditures that it expects to make, if necessary, will be sufficient to fund its operations, capital expenditures and scheduled cash payments under its debt obligations through June 30, 2014. The Company’s ability to pay required monthly installment payments under the Exchanged Note in equity instead of cash is based on certain stock price and trading volume conditions that are outside of the Company’s control. If one or both of these equity conditions are not met (absent a waiver from the lender), the Company may be required to make required monthly installment payments in cash. As of the date of this Form 10-Q, the Company has only made payments to the lender in shares of common stock and as a result, the principal balance has been reduced by $10.6 million through June 30, 2013. If the Company fails one or both of the equity conditions, the Company can still make required payments in its common stock with a waiver from the lender, which has been provided in the past. There is no assurance that the lender will provide any waivers in the future. The Company’s liquidity is highly dependent on its ability to profitably grow revenues through both the acquisition of new customers and growth from its existing customers, manage its operating expenses, continue to make amortization payments under the Exchanged Note in shares of the Company’s common stock, maintain compliance with the covenants and restrictions on its debt obligations (or obtain waivers from our lenders in the event of non-compliance), and raise additional capital, as required. Potential sources of additional capital include sales of its minority investments in Tres Amigas and Blade Dynamics, (see Note 13, “Equity Investments”, for further information about such investments) and obtaining additional financing (with the consent of our lenders, if required). There can be no assurance that sources of additional financing or other forms of liquidity will be available on commercially acceptable terms or at all.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The results of operations for an interim period are not necessarily indicative of the results of operations to be expected for the fiscal year. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the fiscal year ended March 31, 2013 (fiscal 2012) which are contained in the Company’s Annual Report on Form 10-K.</font></p> </div>
CY2013Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2655000
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3027000
CY2013Q2	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2014-03-31
CY2013Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M24D
CY2013Q2	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0021	pure
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2013Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9307000
CY2013Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58300000	shares
CY2013Q2	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	Segment
CY2013Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6100000	shares
CY2013Q2	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	2163000	shares
CY2013Q2	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0.167	pure
CY2013Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-2111000
CY2013Q2	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1151000
CY2013Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	-248000
CY2013Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-10548000
CY2013Q2	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	205000
CY2013Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	69000
CY2013Q2	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1154000
CY2013Q2	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	152000
CY2013Q2	us-gaap	Income Taxes Paid IncomeTaxesPaid	145000
CY2013Q2	us-gaap	Debt Instrument Increase Decrease Other Net DebtInstrumentIncreaseDecreaseOtherNet	10600000
CY2013Q2	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	-74000
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-8850000
CY2013Q2	us-gaap	Interest Paid InterestPaid	216000
CY2013Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-10423000
CY2013Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-35000
CY2013Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-8111000
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-10513000
CY2013Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2861000
CY2013Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-35000
CY2013Q2	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1832000
CY2013Q2	us-gaap	Payments For Restructuring PaymentsForRestructuring	136000
CY2013Q2	us-gaap	Sales Revenue Net SalesRevenueNet	23086000
CY2013Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	97000
CY2013Q2	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-4051000
CY2013Q2	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-5464000
CY2013Q2	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1672000
CY2013Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1211000
CY2013Q2	us-gaap	Inventory Write Down InventoryWriteDown	160000
CY2013Q2	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-10211000
CY2013Q2	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-6635000
CY2013Q2	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	2135000
CY2013Q2	us-gaap	Interest Expense InterestExpense	2100000
CY2013Q2	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	25000
CY2013Q2	us-gaap	Cost Of Revenue CostOfRevenue	17987000
CY2013Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	3774000
CY2013Q2	us-gaap	Restructuring Charges RestructuringCharges	13000
CY2013Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2135000
CY2013Q2	us-gaap	Restructuring Settlement And Impairment Provisions RestructuringSettlementAndImpairmentProvisions	13000
CY2013Q2	us-gaap	Restructuring Costs RestructuringCosts	-27000
CY2013Q2	us-gaap	Other Noncash Expense OtherNoncashExpense	686000
CY2013Q2	us-gaap	Deferred Policy Acquisition Cost Amortization Expense DeferredPolicyAcquisitionCostAmortizationExpense	82000
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	31936000
CY2013Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10827000
CY2013Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	90000
CY2013Q2	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	109000
CY2013Q2	amsc	Weighted Average Shares Of Common Stock Outstanding WeightedAverageSharesOfCommonStockOutstanding	60463000	shares
CY2013Q2	amsc	Number Of Trading Days For Valuation Of Shares NumberOfTradingDaysForValuationOfShares	P10D
CY2013Q2	amsc	Fair Value Assumptions Redeemable FairValueAssumptionsRedeemable	yes
CY2013Q2	amsc	Fair Value Assumptions Dilution Effect FairValueAssumptionsDilutionEffect	yes
CY2013Q2	amsc	Fair Value Assumptions Recovery Rate FairValueAssumptionsRecoveryRate	0.370	pure
CY2013Q2	amsc	Long Term Purchase Commitment Adverse Purchase Commitment Accrual LongTermPurchaseCommitmentAdversePurchaseCommitmentAccrual	300000
CY2013Q2	amsc	Convertible Debt Instrument Redemption Waiting Period ConvertibleDebtInstrumentRedemptionWaitingPeriod	P1Y
CY2013Q2	amsc	Non Cash Interest Expense Issuing Stock At Discount NonCashInterestExpenseIssuingStockAtDiscount	100000
CY2013Q2	amsc	Percentage Of Stock Discount PercentageOfStockDiscount	0.85	pure
CY2013Q2	amsc	Convertible Debt Instrument Contractual Term ConvertibleDebtInstrumentContractualTerm	P30M
CY2013Q2	amsc	Payments In Lieu Of Issuance Of Common Stock For Payroll Taxes PaymentsInLieuOfIssuanceOfCommonStockForPayrollTaxes	-57000
CY2013Q2	amsc	Percentage Volume Condition Met PercentageVolumeConditionMet	0.875	pure
CY2013Q2	amsc	Gain Loss In Change Of Fair Value Of Derivative Instruments And Warrants GainLossInChangeOfFairValueOfDerivativeInstrumentsAndWarrants	469000
CY2013Q2	amsc	Non Cash Interest Expense Amortization Of Debt Discount NonCashInterestExpenseAmortizationOfDebtDiscount	1700000
CY2013Q2	amsc	Convertible Notes Fair Value As Percentage Of Par Value ConvertibleNotesFairValueAsPercentageOfParValue	0.033	pure
CY2012Q3	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P2Y4D
CY2012Q3	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.700	pure
CY2012Q3	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0023	pure
CY2012Q3	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0.150	pure
CY2012Q3	amsc	Fair Value Assumptions Redeemable FairValueAssumptionsRedeemable	yes
CY2012Q3	amsc	Fair Value Assumptions Dilution Effect FairValueAssumptionsDilutionEffect	yes
CY2012Q3	amsc	Fair Value Assumptions Recovery Rate FairValueAssumptionsRecoveryRate	0.300	pure
CY2012Q3	amsc	Percentage Volume Condition Met PercentageVolumeConditionMet	0.510	pure
CY2012Q3	amsc	Convertible Notes Fair Value As Percentage Of Par Value ConvertibleNotesFairValueAsPercentageOfParValue	0.114	pure
CY2012Q4	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P1Y9M4D
CY2012Q4	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.735	pure
CY2012Q4	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0023	pure
CY2012Q4	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0.165	pure
CY2012Q4	amsc	Fair Value Assumptions Redeemable FairValueAssumptionsRedeemable	yes
CY2012Q4	amsc	Fair Value Assumptions Dilution Effect FairValueAssumptionsDilutionEffect	yes
CY2012Q4	amsc	Fair Value Assumptions Recovery Rate FairValueAssumptionsRecoveryRate	0.300	pure
CY2012Q4	amsc	Percentage Volume Condition Met PercentageVolumeConditionMet	0.945	pure
CY2012Q4	amsc	Convertible Notes Fair Value As Percentage Of Par Value ConvertibleNotesFairValueAsPercentageOfParValue	0.049	pure

Files In Submission

Name	View Source	Status
0001193125-13-324142-index-headers.html	Edgar Link	pending
0001193125-13-324142-index.html	Edgar Link	pending
0001193125-13-324142.txt	Edgar Link	pending
0001193125-13-324142-xbrl.zip	Edgar Link	pending
amsc-20130630.xml	Edgar Link	completed
amsc-20130630.xsd	Edgar Link	pending
amsc-20130630_cal.xml	Edgar Link	unprocessable
amsc-20130630_def.xml	Edgar Link	unprocessable
amsc-20130630_lab.xml	Edgar Link	unprocessable
amsc-20130630_pre.xml	Edgar Link	unprocessable
d561877d10q.htm	Edgar Link	pending
d561877dex101.htm	Edgar Link	pending
d561877dex311.htm	Edgar Link	pending
d561877dex312.htm	Edgar Link	pending
d561877dex321.htm	Edgar Link	pending
d561877dex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
g561877p1.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R1.xml	Edgar Link	unprocessable
R10.htm	Edgar Link	pending
R10.xml	Edgar Link	unprocessable
R11.htm	Edgar Link	pending
R11.xml	Edgar Link	unprocessable
R12.htm	Edgar Link	pending
R12.xml	Edgar Link	unprocessable
R13.htm	Edgar Link	pending
R13.xml	Edgar Link	unprocessable
R14.htm	Edgar Link	pending
R14.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R15.xml	Edgar Link	unprocessable
R16.htm	Edgar Link	pending
R16.xml	Edgar Link	unprocessable
R17.htm	Edgar Link	pending
R17.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R18.xml	Edgar Link	unprocessable
R19.htm	Edgar Link	pending
R19.xml	Edgar Link	unprocessable
R2.htm	Edgar Link	pending
R2.xml	Edgar Link	unprocessable
R20.htm	Edgar Link	pending
R20.xml	Edgar Link	unprocessable
R21.htm	Edgar Link	pending
R21.xml	Edgar Link	unprocessable
R22.htm	Edgar Link	pending
R22.xml	Edgar Link	unprocessable
R23.htm	Edgar Link	pending
R23.xml	Edgar Link	unprocessable
R24.htm	Edgar Link	pending
R24.xml	Edgar Link	unprocessable
R25.htm	Edgar Link	pending
R25.xml	Edgar Link	unprocessable
R26.htm	Edgar Link	pending
R26.xml	Edgar Link	unprocessable
R27.htm	Edgar Link	pending
R27.xml	Edgar Link	unprocessable
R28.htm	Edgar Link	pending
R28.xml	Edgar Link	unprocessable
R29.htm	Edgar Link	pending
R29.xml	Edgar Link	unprocessable
R3.htm	Edgar Link	pending
R3.xml	Edgar Link	unprocessable
R30.htm	Edgar Link	pending
R30.xml	Edgar Link	unprocessable
R31.htm	Edgar Link	pending
R31.xml	Edgar Link	unprocessable
R32.htm	Edgar Link	pending
R32.xml	Edgar Link	unprocessable
R33.htm	Edgar Link	pending
R33.xml	Edgar Link	unprocessable
R34.htm	Edgar Link	pending
R34.xml	Edgar Link	unprocessable
R35.htm	Edgar Link	pending
R35.xml	Edgar Link	unprocessable
R36.htm	Edgar Link	pending
R36.xml	Edgar Link	unprocessable
R37.htm	Edgar Link	pending
R37.xml	Edgar Link	unprocessable
R38.htm	Edgar Link	pending
R38.xml	Edgar Link	unprocessable
R39.htm	Edgar Link	pending
R39.xml	Edgar Link	unprocessable
R4.htm	Edgar Link	pending
R4.xml	Edgar Link	unprocessable
R40.htm	Edgar Link	pending
R40.xml	Edgar Link	unprocessable
R41.htm	Edgar Link	pending
R41.xml	Edgar Link	unprocessable
R42.htm	Edgar Link	pending
R42.xml	Edgar Link	unprocessable
R43.htm	Edgar Link	pending
R43.xml	Edgar Link	unprocessable
R44.htm	Edgar Link	pending
R44.xml	Edgar Link	unprocessable
R45.htm	Edgar Link	pending
R45.xml	Edgar Link	unprocessable
R46.htm	Edgar Link	pending
R46.xml	Edgar Link	unprocessable
R47.htm	Edgar Link	pending
R47.xml	Edgar Link	unprocessable
R48.htm	Edgar Link	pending
R48.xml	Edgar Link	unprocessable
R49.htm	Edgar Link	pending
R49.xml	Edgar Link	unprocessable
R5.htm	Edgar Link	pending
R5.xml	Edgar Link	unprocessable
R50.htm	Edgar Link	pending
R50.xml	Edgar Link	unprocessable
R51.htm	Edgar Link	pending
R51.xml	Edgar Link	unprocessable
R52.htm	Edgar Link	pending
R52.xml	Edgar Link	unprocessable
R53.htm	Edgar Link	pending
R53.xml	Edgar Link	unprocessable
R54.htm	Edgar Link	pending
R54.xml	Edgar Link	unprocessable
R55.htm	Edgar Link	pending
R55.xml	Edgar Link	unprocessable
R56.htm	Edgar Link	pending
R56.xml	Edgar Link	unprocessable
R57.htm	Edgar Link	pending
R57.xml	Edgar Link	unprocessable
R58.htm	Edgar Link	pending
R58.xml	Edgar Link	unprocessable
R59.htm	Edgar Link	pending
R59.xml	Edgar Link	unprocessable
R6.htm	Edgar Link	pending
R6.xml	Edgar Link	unprocessable
R60.htm	Edgar Link	pending
R60.xml	Edgar Link	unprocessable
R61.htm	Edgar Link	pending
R61.xml	Edgar Link	unprocessable
R62.htm	Edgar Link	pending
R62.xml	Edgar Link	unprocessable
R7.htm	Edgar Link	pending
R7.xml	Edgar Link	unprocessable
R8.htm	Edgar Link	pending
R8.xml	Edgar Link	unprocessable
R9.htm	Edgar Link	pending
R9.xml	Edgar Link	unprocessable
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AMSC
AMERICAN SUPERCONDUCTOR CORP /DE/ Stock $amsc

2013 Q2 Form 10-Q Financial Statement

#000119312513324142 Filed on August 07, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMSC AMERICAN SUPERCONDUCTOR CORP /DE/ Stock $amsc

2013 Q2 Form 10-Q Financial Statement

#000119312513324142 Filed on August 07, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMSC
AMERICAN SUPERCONDUCTOR CORP /DE/ Stock $amsc